Span Divergent Ltd SHARE PRICE [LIVE]
Open: | |
High: | |
Low: |
MKT Cap: | |
52-wk High: | |
52-wk Low: |
Prev close: | |
P/E: | |
Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
Name | Dec 22 | Sep 22 |
---|---|---|
Promoters (Change:-0.05) | 64.01% | 64.06% |
FIIs (Change:0.00) | 0% | 0% |
Mutual Funds (Change:0.00) | 0% | 0% |
Insurance Companies (Change:0.00) | 0% | 0% |
Other DIIs (Change:0.00) | 0% | 0% |
Non Institution (Change:0.05) | 35.99% | 35.94% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in Span Divergent Ltd
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
SDL News
Frequently Asked Questions
What is the Share price of Span Divergent Ltd (SDL)?
Can I buy Span Divergent Ltd (SDL) shares?
How do I buy Span Divergent Ltd (SDL) from Angel One?
- Direct investment: You can buy Span Divergent Ltd (SDL) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Span Divergent Ltd (SDL) shares.
In which sector do Span Divergent Ltd (SDL) belong?
About SDL
Today's live share price for Span Divergent Ltd is NSE: N/A, BSE: ₹ 13.33 with a current market capitalization of .
Incorporated on 31st March 1980 as Private Ltd. Co. and converted into a Public Ltd. Co. on 14th August 1993. Promoted by Dr.P.K.Desai. The Company is engaged in manufacturing a wide range of microbiological, immunological and bio-chemical diognostic reagents, plastic accessories and allied products in its plant at Udhna. The Company completed expansion-cum-modernisation and mechanisation of packing activities at Udhna. Acquiring three plots of land at GIDC Sachin admeasuring 33,897 sq. mtrs. which is situated near the State Highway and National Highway No.8.This project was finance by way of internal accruals of Rs.31.62 lakhs and balance from Term Loans of Rs.30 lakhs. The Company entered into the technical arrangement with Bioprobe Netherland, Path U.S.A. Dynajen U.S.A. for manufacturing HIV Dipsticks, Myco-dot, Monoclonal anitbodies. Company launched several new products developed by its R & D Center such as One Step Lateral Chromotography Based Assay for monitoring of pregnancy and Hepatitis to be marketed under the brand name of CRYSTAL as well as HIV Flow Through. The continuation distributorship arrangements with Murex Biotech UK Ltd which is now subsidiary of Abbott Diagnostics USA will also generate substantial business from the nitche market of the Blood Bank Segment.
Read more